Victory Capital Management Inc. Acquires 4,575 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Victory Capital Management Inc. grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 296,080 shares of the biopharmaceutical company’s stock after purchasing an additional 4,575 shares during the quarter. Victory Capital Management Inc. owned approximately 0.25% of Catalyst Pharmaceuticals worth $6,179,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after buying an additional 33,888 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Catalyst Pharmaceuticals by 13.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after buying an additional 50,888 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $1,185,000. Redhawk Wealth Advisors Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $1,273,000. Finally, Spire Wealth Management lifted its holdings in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 13,429 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CPRX. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.50.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.7 %

NASDAQ CPRX opened at $21.02 on Friday. The stock has a market capitalization of $2.55 billion, a P/E ratio of 17.81, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $24.64. The firm has a 50-day moving average price of $22.26 and a 200 day moving average price of $21.52.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.